NR1H3 and fatty liver disease: As a dual LXR/FXR receptor activator, withaferin A activates both LXR-α and FXR, inducing their canonical target genes (ABCA1 and ABCB11) and inhibiting diet-induced hepatic steatosis, steatohepatitis, and fibrosis [122].